INFORMATION CONTAINED IN THIS FORM 6-K REPORT
This Amendment No. 1 to the 6-K of Kazia Therapeutics Limited (the “Company”) that was filed with the Securities and Exchange Commission on February 28, 2023 is being filed solely to include interactive data files in inline eXtensible Business Reporting Language (iXBRL) in connection with the Company’s interim results for the half-year ended December 31, 2022.
Attached as Exhibit 99.1 of this Report on Form 6-K is a copy of the Company’s interim results for the half-year ended December 31, 2022, which are hereby incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
Exhibit |
Description | |
99.1 | Half-year report for the six months ended December 31, 2022 | |
101.INS | XBRL Instance Document | |
101.SCH | XBRL Taxonomy Extension Schema Document | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited (Registrant)
/s/ Karen Krumeich
Karen Krumeich
Chief Financial Officer
Date: 9 March 2023
Kazia Therapeutics Limited Appendix 4D Half-year report |
Name of entity: | Kazia Therapeutics Limited | |
ABN: | 37 063 259 754 | |
Reporting period: | For the half-year ended 31 December 2022 | |
Previous period: | For the half-year ended 31 December 2021 |
$ |
||||||||||||||
Loss from ordinary activities after tax attributable to the owners of Kazia Therapeutics Limited |
up | 2.9 | % | to | (13,586,027 | ) | ||||||||
Loss for the half-year attributable to the owners of Kazia Therapeutics Limited |
up | 2.9 | % | to | (13,586,027 | ) |
Reporting period Cents |
Previous period Cents Restated* |
|||||||
Net tangible assets per ordinary security |
(4.05 | ) | (0.62 | ) | ||||
Kazia Therapeutics Limited Appendix 4D Half-year report |
Signed | /s/ Iain Ross |
Date: 28 February 2023 |
Kazia Therapeutics Limited Directors’ report 31 December 2022 |
Kazia Therapeutics Limited Directors’ report 31 December 2022 |
Kazia Therapeutics Limited Directors’ report 31 December 2022 |
Kazia Therapeutics Limited Directors’ report 31 December 2022 |
/s/ Iain Ross |
||||
Iain Ross |
||||
Chairman |
||||
28 February 2023 |
||||
Sydney |
|
Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 www.bdo.com.au |
Level 11, 1 Margaret Street Sydney NSW 2000 Australia |
1. | No contraventions of the auditor independence requirements of the Corporations Act 2001 |
2. | No contraventions of any applicable code of professional conduct in relation to the review. |
Kazia Therapeutics Limited Contents 31 December 2022 |
Statement of profit or loss and other comprehensive income |
7 | |||
Statement of financial position |
8 | |||
Statement of changes in equity |
9 | |||
Statement of cash flows |
11 | |||
Notes to the financial statements |
12 | |||
Directors’ declaration |
22 | |||
Independent auditor’s review report to the members of Kazia Therapeutics Limited |
23 |
Kazia Therapeutics Limited Statement of profit or loss and other comprehensive income For the half-year ended 31 December 2022 |
Consolidated |
||||||||||||
Note |
December 2022 |
December 2021 Restated * |
||||||||||
$ |
$ |
|||||||||||
Revenue and other income |
||||||||||||
Other income |
5 | |||||||||||
Finance Income |
||||||||||||
Expenses |
||||||||||||
Research and development expense |
( |
) | ( |
) | ||||||||
General and administrative expense |
( |
) | ( |
) | ||||||||
Loss on revaluation of contingent consideration |
( |
) | ( |
) | ||||||||
|
|
|
|
|||||||||
Loss before income tax benefit |
( |
) | ( |
) | ||||||||
Income tax benefit |
||||||||||||
|
|
|
|
|||||||||
Loss after income tax benefit for the half-year attributable to the owners of Kazia Therapeutics Limited |
( |
) | ( |
) | ||||||||
Other comprehensive income |
||||||||||||
Items that may be reclassified subsequently to profit or loss |
||||||||||||
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax |
||||||||||||
|
|
|
|
|||||||||
Other comprehensive income for the half-year, net of tax |
||||||||||||
|
|
|
|
|||||||||
Total comprehensive income for the half-year attributable to the owners of Kazia Therapeutics Limited |
( |
) | ( |
) | ||||||||
|
|
|
|
|||||||||
* The comparative information has been restated as a result of the prior period error discussed in note 3. |
| |||||||||||
Cents |
Cents |
|||||||||||
Basic earnings per share |
20 | ( |
) | ( |
) | |||||||
Diluted earnings per share |
20 | ( |
) | ( |
) |
Kazia Therapeutics Limited Statement of financial position As at 31 December 2022 |
Consolidated |
||||||||||||
Note |
December 2022 |
June 2022 Restated * |
||||||||||
$ |
$ |
|||||||||||
Assets |
||||||||||||
Current assets |
||||||||||||
Cash and cash equivalents |
7 | |||||||||||
Trade and other receivables |
8 | |||||||||||
Other assets |
9 | |||||||||||
|
|
|
|
|||||||||
Total current assets |
||||||||||||
|
|
|
|
|||||||||
Non-current assets |
||||||||||||
Intangibles |
10 | |||||||||||
Trade and other receivables |
11 | |||||||||||
|
|
|
|
|||||||||
Total non-current assets |
||||||||||||
|
|
|
|
|||||||||
Total assets |
||||||||||||
|
|
|
|
|||||||||
Liabilities |
||||||||||||
Current liabilities |
||||||||||||
Trade and other payables |
12 | |||||||||||
Borrowings |
13 | |||||||||||
Employee benefits |
||||||||||||
Contingent consideration |
14 | |||||||||||
|
|
|
|
|||||||||
Total current liabilities |
||||||||||||
|
|
|
|
|||||||||
Non-current liabilities |
||||||||||||
Deferred tax |
15 | |||||||||||
Employee benefits |
||||||||||||
Contingent consideration |
16 | |||||||||||
|
|
|
|
|||||||||
Total non-current liabilities |
||||||||||||
|
|
|
|
|||||||||
Total liabilities |
||||||||||||
|
|
|
|
|||||||||
Net assets |
||||||||||||
|
|
|
|
|||||||||
Equity |
||||||||||||
Contributed equity |
17 | |||||||||||
Reserves |
||||||||||||
Accumulated losses |
( |
) | ( |
) | ||||||||
|
|
|
|
|||||||||
Total equity |
||||||||||||
|
|
|
|
* | The comparative information has been restated as a result of the prior period error discussed in note 3. |
Kazia Therapeutics Limited Statement of changes in equity For the half-year ended 31 December 2022 |
Issued capital |
Other contributed equity |
Share based payment reserve |
Foreign currency translation reserve |
Accumulated losses |
Total equity |
|||||||||||||||||||
Consolidated |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||
Balance at 1 July 2021 |
( |
) | ( |
) | ||||||||||||||||||||
Adjustment for correction of error (note 3) |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance at 1 July 2021 - restated |
( |
) | ( |
) | ||||||||||||||||||||
Loss after income tax benefit for the half-year |
( |
) | ( |
) | ||||||||||||||||||||
Other comprehensive income for the half-year, net of tax |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total comprehensive income for the half-year |
( |
) | ( |
) | ||||||||||||||||||||
Transactions with owners in their capacity as owners: |
||||||||||||||||||||||||
Immaterial reclassification |
( |
) | ||||||||||||||||||||||
Exercise of options |
( |
) | ||||||||||||||||||||||
Employee share-based payment options - expired |
( |
) | ||||||||||||||||||||||
Employee share-based payment options |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance at 31 December 2021 |
( |
) | ( |
) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Kazia Therapeutics Limited Statement of changes in equity For the half-year ended 31 December 2022 |
Issued capital |
Other contributed equity |
Share based payment reserve |
Foreign currency translation reserve |
Accumulated losses |
Total equity |
|||||||||||||||||||
Consolidated |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||
Balance at 1 July 2022 |
( |
) | ( |
) | ||||||||||||||||||||
Adjustment for correction of error (note 3) |
( |
) | ( |
) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance at 1 July 2022 - restated |
( |
) | ( |
) | ||||||||||||||||||||
Loss after income tax benefit for the half-year |
( |
) | ( |
) | ||||||||||||||||||||
Other comprehensive income for the half-year, net of tax |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total comprehensive income for the half-year |
( |
) | ( |
) | ||||||||||||||||||||
Issue of shares |
||||||||||||||||||||||||
Share issue costs |
( |
) | ( |
) | ||||||||||||||||||||
Transactions with owners in their capacity as owners: |
||||||||||||||||||||||||
Employee share-based payment options - expired |
( |
) | ||||||||||||||||||||||
Employee share-based payment options |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance at 31 December 2022 |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Kazia Therapeutics Limited Statement of cash flows For the half-year ended 31 December 2022 |
Consolidated |
||||||||||||
Note |
December 2022 |
December 2021 |
||||||||||
$ |
$ |
|||||||||||
Cash flows from operating activities |
||||||||||||
Payments to suppliers (inclusive of GST) |
( |
) | ( |
) | ||||||||
Net cash used in operating activities |
21 | ( |
) | ( |
) | |||||||
Cash flows from investing activities |
||||||||||||
Payment of milestone relating to contingent consideration |
16 | ( |
) | |||||||||
Net cash used in investing activities |
( |
) | ||||||||||
Cash flows from financing activities |
||||||||||||
Proceeds from issue of shares (net of costs) |
17 | |||||||||||
Net cash from financing activities |
||||||||||||
Net decrease in cash and cash equivalents |
( |
) | ( |
) | ||||||||
Cash and cash equivalents at the beginning of the financial half-year |
||||||||||||
Effects of exchange rate changes on cash and cash equivalents |
( |
) | ||||||||||
Cash and cash equivalents at the end of the financial half-year |
7 | |||||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 Note 1. Significant accounting policies (continued) |
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
30 June 2022 |
Increase/ (decrease) |
30 June 2022 Restated |
||||||||||
Intangibles - licensing agreement EVT-801 |
( |
) | ||||||||||
Less Accumulated amortisation |
( |
) | ( |
) | ||||||||
( |
) |
|||||||||||
Current contingent consideration EVT-801 |
( |
) | ( |
) | ||||||||
Non-Current contingent consideration EVT-801 |
( |
) | ( |
) | ||||||||
( |
) |
( |
) | |||||||||
Net Assets |
( |
) |
||||||||||
Accumulated losses |
( |
) | ( |
) | ( |
) | ||||||
Total equity |
( |
) |
||||||||||
Consolidated statement of profit and loss |
31 December 2021 |
(Increase)/ Decrease |
31 December 2021 Restated |
|||||||||
Research and development expense (Amortisation) |
( |
) | ( |
) | ||||||||
General and administrative expense (interest and foreign exchange impact) |
( |
) | ( |
) | ( |
) | ||||||
Loss before tax |
( |
) |
( |
) |
( |
) | ||||||
Income tax benefit |
||||||||||||
Loss after tax |
( |
) |
( |
) |
( |
) | ||||||
Impact on basic and diluted earnings per share increase/(decrease) in earning per share |
Cents |
Cents |
Cents |
|||||||||
Basic loss for the year attributable to equity holders |
( |
) | ( |
) | ( |
) | ||||||
Diluted loss for the year attributable to equity holders |
( |
) | ( |
) | ( |
) |
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
Consolidated |
||||||||
December 2022 |
December 2021 |
|||||||
$ |
$ |
|||||||
Government grants |
||||||||
Bad debt recovery |
||||||||
Other income |
||||||||
Consolidated |
||||||||
December 2022 $ |
December 2021 Restated * $ |
|||||||
Loss before income tax includes the following specific expenses: |
||||||||
Amortisation |
||||||||
Paxalisib licensing agreement |
||||||||
EVT-801 licensing agreement |
||||||||
Total amortisation |
||||||||
Interest expense |
||||||||
Contingent consideration |
||||||||
Superannuation expense |
||||||||
Defined contribution superannuation expense |
||||||||
Employee benefits expense excluding superannuation |
||||||||
Employee benefits expense excluding superannuation |
||||||||
Consolidated |
||||||||
December 2022 |
June 2022 |
|||||||
$ |
$ |
|||||||
Cash at bank and on hand |
||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
Consolidated |
||||||||
December 2022 |
June 2022 |
|||||||
$ |
$ |
|||||||
GST refundable |
||||||||
Paxalisib Phase II clinical trial refund |
||||||||
Deposit paid |
||||||||
Consolidated |
||||||||
December 2022 |
June 2022 |
|||||||
$ |
$ |
|||||||
Prepayments |
||||||||
Consolidated |
||||||||
December 2022 |
June 2022 Restated * |
|||||||
$ |
$ |
|||||||
Paxalisib Licensing agreement - at acquired fair value |
||||||||
Less: Accumulated amortisation |
( |
) | ( |
) | ||||
EVT-801 Licensing agreement - at cost |
||||||||
Less: Accumulated amortisation |
( |
) | ( |
) | ||||
EVT801 licensing agreement Restated* |
Paxalisib licensing agreement |
Total |
||||||||||
Consolidated |
$ |
$ |
$ |
|||||||||
Balance at 1 July 2022 |
||||||||||||
Amortisation expense |
( |
) | ( |
) | ( |
) | ||||||
Balance at 31 December 2022 |
||||||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
Consolidated |
||||||||
December |
June |
|||||||
2022 |
2022 |
|||||||
$ |
$ |
|||||||
GBM Agile deposit |
||||||||
Corporate credit card deposit |
||||||||
Consolidated |
||||||||
December |
June |
|||||||
2022 |
2022 |
|||||||
$ |
$ |
|||||||
Trade payables |
||||||||
Accrued and other payables |
||||||||
Consolidated |
||||||||
December |
June |
|||||||
2022 |
2022 |
|||||||
$ |
$ |
|||||||
Insurance premium funding |
||||||||
Consolidated |
||||||||
December |
June 2022 |
|||||||
2022 |
Restated * |
|||||||
$ |
$ |
|||||||
Contingent consideration - Paxalisib |
||||||||
Contingent consideration – EVT801 |
||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
Consolidated |
||||||||
December |
June 2022 |
|||||||
2022 |
Restated * |
|||||||
$ |
$ |
|||||||
Deferred tax liability |
||||||||
Amount expected to be settled after more than 12 months |
||||||||
Movements: |
||||||||
Opening balance |
||||||||
Credited to profit or loss |
( |
) | ( |
) | ||||
Closing balance |
||||||||
Consolidated |
||||||||
December |
June 2022 |
|||||||
2022 |
Restated * |
|||||||
$ |
$ |
|||||||
Contingent consideration - Paxalisib |
||||||||
Contingent consideration - EVT801 |
||||||||
Consolidated |
||||||||
December |
June 2022 |
|||||||
2022 |
Restated * |
|||||||
$ |
$ |
|||||||
Reconciliation of the balance at the beginning and end of the reporting period is set out below: |
||||||||
Contingent consideration at start of period (current and non-current) |
||||||||
Payment of EVT801 milestone |
— | ( |
) | |||||
Interest |
||||||||
Foreign currency loss |
( |
) | ||||||
Loss on revaluation of contingent consideration |
||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 Note 16. Contingent consideration - non-current (continued) |
Consolidated |
||||||||||||||||
December |
June 2022 |
December |
June 2022 |
|||||||||||||
2022 |
Restated * |
2022 |
Restated * |
|||||||||||||
Shares |
Shares |
$ |
$ |
|||||||||||||
Ordinary shares - fully paid |
||||||||||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 Note 17. Contributed equity (continued) |
Details |
Date |
Shares |
Issue price |
$ |
||||||||||
Balance |
1 July 2022 | |||||||||||||
ATM issue of shares No. 8 |
7 July 2022 | $ | ||||||||||||
ATM issue of shares No. 9 |
8 August 2022 | $ | ||||||||||||
ATM issue of shares No. 10 |
9 August 2022 | $ | ||||||||||||
ATM issue of shares No. 11 |
10 August 2022 | $ | ||||||||||||
ATM issue of shares No. 12 |
11 August 2022 | $ | ||||||||||||
ATM issue of shares No. 13 |
12 August 2022 | $ | ||||||||||||
ATM issue of shares No. 14 |
12 September 2022 | $ | ||||||||||||
ATM issue of shares No. 15 |
13 September 2022 | $ | ||||||||||||
Scientific Advisory Board issue |
14 September 2022 | $ | ||||||||||||
ATM issue of shares No. 16 |
7 October 2022 | $ | ||||||||||||
ATM issue of shares No. 17 |
28 October 2022 | $ | ||||||||||||
Less: share issue transaction costs |
— | $ | ( |
) | ||||||||||
Balance |
31 December 2022 | |||||||||||||
Kazia Therapeutics Limited Notes to the financial statements 31 December 2022 |
Consolidated December 2022 |
Consolidated December 2021 Restated* |
|||||||
$ |
$ |
|||||||
Loss after income tax attributable to the owners of Kazia Therapeutics Limited |
( |
) | ( |
) | ||||
Number |
Number |
|||||||
Weighted average number of ordinary shares used in calculating basic earnings per share |
||||||||
Weighted average number of ordinary shares used in calculating diluted earnings per share |
||||||||
Cents |
Cents |
|||||||
Basic earnings per share |
( |
) | ( |
) | ||||
Diluted earnings per share |
( |
) | ( |
) |
Consolidated |
||||||||
December 2022 $ |
December 2021 Restated* $ |
|||||||
Loss after income tax benefit for the half-year |
( |
) | ( |
) | ||||
Adjustments for: |
||||||||
Depreciation and amortisation |
||||||||
Share—based payments |
||||||||
Foreign exchange differences |
( |
) | ||||||
Loss on contingent consideration |
||||||||
Contingent consideration interest |
||||||||
Change in operating assets and liabilities: Increase in trade and other receivables |
( |
) | ( |
) | ||||
(Increase)/decrease in prepayments |
( |
) | ||||||
Decrease in GBM Agile deposit |
— | |||||||
Increase in insurance premium funding |
— | |||||||
(Decrease)/increase in trade and other payables |
( |
) | ||||||
Decrease in deferred tax liabilities |
( |
) | ( |
) | ||||
Increase in employee benefits |
||||||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
Kazia Therapeutics Limited Directors’ declaration 31 December 2022 |
• | the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 ‘Interim Financial Reporting’, the Corporations Regulations 2001 and other mandatory professional reporting requirements; |
• | the attached financial statements and notes give a true and fair view of the consolidated entity’s financial position as at 31 December 2022 and of its performance for the financial half-year ended on that date; and |
• | there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable. |
/s/ Iain Ross |
||||
Iain Ross | ||||
Chairman |
Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 www.bdo.com.au |
Level 11, 1 Margaret Street Sydney NSW 2000 Australia |
(i) | Giving a true and fair view of the Group’s financial position as at 31 December 2022 and of its financial performance for the half-year ended on that date; and |
(ii) | Complying with Accounting Standard AASB 134 Interim Financial Reporting Corporations Regulations 2001. |
Cover |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Document Information [Line Items] | |
Document Type | 6-K/A |
Amendment Flag | false |
Document Period End Date | Dec. 31, 2022 |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | Q2 |
Entity Registrant Name | Kazia Therapeutics Limited |
Entity Central Index Key | 0001075880 |
Current Fiscal Year End Date | --06-30 |
Statement of financial position - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
Dec. 31, 2021 |
---|---|---|---|
Current assets | |||
Cash and cash equivalents | $ 4,390,523 | $ 7,361,112 | $ 15,188,957 |
Trade and other receivables | 741,128 | 90,975 | |
Other | 784,557 | 156,153 | |
Total current assets | 5,916,208 | 7,608,240 | |
Non-current assets | |||
Intangibles | 18,204,147 | 19,138,858 | |
Trade and other receivables | 3,715,248 | 7,300,870 | |
Total non-current assets | 21,919,395 | 26,439,728 | |
Total assets | 27,835,603 | 34,047,968 | |
Current liabilities | |||
Trade and other payables | 3,148,768 | 3,760,120 | |
Borrowings | 552,315 | 0 | |
Employee benefits | 442,835 | 166,196 | |
Contingent consideration | 1,438,461 | 758,840 | |
Total current liabilities | 5,582,379 | 4,685,156 | |
Non-Current liabilities | |||
Deferred tax | 2,424,815 | 2,560,361 | 2,928,441 |
Employee benefits | 126,907 | 318,983 | |
Contingent consideration | 8,118,317 | 8,208,945 | |
Total non-current liabilities | 10,670,039 | 11,088,289 | |
Total liabilities | 16,252,418 | 15,773,445 | |
Net assets | 11,583,185 | 18,274,523 | |
Equity | |||
Contributed equity | 90,343,718 | 84,480,249 | |
Reserves | 3,439,399 | 2,411,665 | |
Accumulated losses | (82,199,932) | (68,617,391) | |
Total equity | $ 11,583,185 | $ 18,274,523 | $ 25,315,899 |
Statement of cash flows - AUD ($) |
6 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
Cash flows from operating activities | ||
Payments to suppliers (inclusive of GST) | $ (8,806,148) | $ (11,391,410) |
Net cash used in operating activities | (8,806,148) | (11,391,410) |
Cash flows from investing activities | ||
Payment of milestone relating to contingent consideration | 0 | (1,582,278) |
Net cash used in investing activities | 0 | (1,582,278) |
Cash flows from financing activities | ||
Proceeds from issue of shares (net of costs) | 5,850,869 | 16,700 |
Net cash from financing activities | 5,850,869 | 16,700 |
Net decrease in cash and cash equivalents | (2,955,279) | (12,956,988) |
Cash and cash equivalents at the beginning of the financial half-year | 7,361,112 | 27,586,760 |
Effects of exchange rate changes on cash and cash equivalents | (15,310) | 559,185 |
Cash and cash equivalents at the end of the financial half-year | $ 4,390,523 | $ 15,188,957 |
Significant accounting policies |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Text block [abstract] | |
Significant accounting policies | Note 1. Significant accounting policies These general purpose financial statements for the interim half-year reporting period ended 31 December 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 ‘Interim Financial Reporting’ and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 ‘Interim Financial Reporting’. These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated. New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Going concern During the half year ended 31 December 2022 the consolidated entity experienced net cash outflows from operating activities of $8,806,148 (December 2021: $11,391,410) and incurred a loss after tax of $13,586,027 (December 2021 restated: $13,201,848). As at 31 December 2022 the consolidated entity had cash in hand and at bank of $4,390,523. The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. An ‘at-the-market’ equity program (ATM) with Oppenheimer & Co. Inc. (Oppenheimer), as sales agent was established in May 2022. Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million of its ordinary shares, in the form of American Depository Shares (ADSs), with each ADS representing ten ordinary shares. Kazia entered into an Equity Distribution Agreement, dated 22 April 2022 (the Sales Agreement), with Oppenheimer, who acts as sales agent. As at 31 December 2022 net proceeds of A$9,560,357 have been raised. On 3 January 2023 a deposit of US$428,096 was received from Labcorp Early Development Laboratories Inc. representing the refund due on the completion of the Paxalisib Phase II trial. On 1 6 January 2023 Kazia announced a placement to professional and sophisticated investors and the launch of an associated Share Purchase Plan for eligible shareholders. The placement of A$4,500,000, comprised of an unconditional placement of A$2,792,572 at $0.11 per share; and a conditional placement of A$1,707,428 at $0.11 per share, and was approved by shareholders at the Extraordinary General Meeting on 24 February 2023. Each placement was made to professional and sophisticated investors. The Placement was not underwritten. In addition, eligible shareholders were offered the opportunity to acquire up to A$30,000 of new shares through a Share Purchase Plan (SPP). All new shares issued under the Placement and the SPP ranked equally with the existing ordinary shares. Funding will be used to drive Kazia’s clinical program toward several critical inflection points through CY2023, including the final data read out on the paxalisib GBM AGILE study and for general working capital purposes. Accordingly the directors have prepared the financial statements on a going concern basis. While the Company’s current cash balance is not sufficient to fund the operations for a period of 12 months from the date of this report, the directors have prepared the financial statements on a going concern basis as they are confident of the Company’s ability to raise additional funding, via licensing and partnering activities, obtaining of grant funding or raising additional capital from investors. Should the above assumptions not prove to be appropriate, there is material uncertainty related to events or conditions that may cast significant doubt whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. |
Critical accounting judgements, estimates and assumptions |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Text block [abstract] | |
Critical accounting judgements, estimates and assumptions | Note 2. Critical accounting judgements, estimates and assumptions When preparing the half-year financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management and will seldom equal the estimated results. The judgments, estimates and assumptions applied in the half-year financial statements, including key sources of estimation uncertainty were the same as those applied in the Group’s last annual financial statements for the year ended 30 June 2022. |
Restatement of comparatives |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restatement of comparatives | Note 3. Restatement of comparatives Correction of error During the December 2022 review, the calculation of the EVT-801 asset and its contingent consideration was found to contain errors as discounting for the time value of money was not taken into account on initial recognition. The contractual payments in relation to the milestones gave rise to a financial liability at acquisition. The cost of the intangible asset should comprise the initial payment plus an amount reflecting the fair value of the other contingent payments determined using a probability–weighted estimation. These values should be discounted to reflect the time value of money at the time of acquisition in April 2021. Management have utilised an Incremental Borrowing Rate of 6% to discount the future cash flows. The Incremental Borrowing Rate reflects the assumed credit rating of the Company. The error resulted in a material overstatement of the EVT-801 asset and a corresponding overstatement of the liability at acquisition. The impact of this error is noted below with the restated balances disclosed in note 10,14 and 16:
|
Operating segments |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Text block [abstract] | |
Operating segments | Note 4. Operating segments Identification of reportable operating segments The consolidated entity’s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (‘CODM’)) in assessing performance and in determining the allocation of resources. The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position. |
Other income |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other income | Note 5. Other income
|
Expenses |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expenses | Note 6. Expenses
|
Cash and cash equivalents |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents | Note 7. Cash and cash equivalents
|
Trade and other receivables |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade and other receivables | Note 8. Trade and other receivables
The Paxalisib Phase II clinical trial refund is the amount owing (US$428,096) from Labcorp Early Development Laboratories Inc. after their final reconciliation of trial costs. Funds were received on 3 January 2023. |
Other assets |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current assets - other | Note 9. Other assets
|
Intangibles |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangibles | Note 10. Intangibles
Reconciliations Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
|
Trade and other receivables - non-current |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade and other receivables - non-current | Note 11. Trade and other receivables - non-current
|
Trade and other payables |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statement [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trade and other payables | Note 12. Trade and other payables
|
Borrowings |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of borrowings [text block] | Note 13. Borrowings
|
Contingent consideration |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statement [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contingent consideration | Note 14. Contingent consideration
See also Note 16 setting out non-current contingent consideration. |
Deferred tax |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred tax | Note 15. Deferred tax
|
Contingent consideration - non-current |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contingent consideration - non-current | Note 16. Contingent consideration - non-current
A portion of the discount applied to anticipated future payments has unwound, with the resultant increase in contingent consideration being recognised in profit and loss.
Contingent consideration - paxalisib During the 2017 financial year, the consolidated entity acquired 100% of the issued shares in Glioblast Pty Ltd, a privately held, neuro-oncology-focused Australian biotechnology company. On the same day, Kazia entered into a worldwide licensing agreement with Genentech to develop and commercialise GDC-0084, now known as paxalisib. The Glioblast acquisition contains four contingent milestone payments, the first two milestone payments are to be settled with Kazia shares, and the third and fourth milestone payments are to be settled with either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the value of $1,250,000. The Genentech agreement comprises of one milestone payment payable on the first commercial licensed product sale, in the amount of $1,394,000. Each milestone payment is probability weighted for valuation purposes. The milestone payments are discounted to present value, using a discount rate of 15% (previously 35%) per annum. The discount rate was considered at 30 June 2021 and it was determined that the risk of the asset, and therefore of the milestones being met, has been considerably decreased as a result of paxalisib entering the pivotal GBM Agile trial, which is progressing well, and the license transaction with Simcere Pharmaceutical Group, which provides an external validation of paxalisib. Accordingly, the discount rate applied to future expected cash flows has been revised downwards. Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance, and are not considered as part of the consideration in relation to the Genentech agreement. Contingent consideration - EVT801 The acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being booked as a current or non-current liability at period end, according to the estimated payment date. The milestone payments that have a probability of 100% are discounted to present value, using a discount rate of 6% per annum. The discount rate was considered based on the incremental borrowing rate at the time of acquisition. Milestones where the payment is not considered probable at year end have not been accounted for as a liability. The total amount of milestone payments not booked at year end amounts to €300,500,000 ($472,558,578). |
Contributed equity |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contributed equity | Note 17. Contributed equity
19
Movements in spare share capital
Share buy-back There is no current on-market share buy-back. |
Dividends |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Text block [abstract] | |
Dividends | Note 18. Dividends There were no dividends paid, recommended or declared during the current or previous financial half-year. |
Events after the reporting period |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Text block [abstract] | |
Events after the reporting period | Note 19. Events after the reporting period On 3 January 2023 a deposit of US$428,096 was received from Labcorp Early Development Laboratories Inc. representing the refund due on the completion of the Paxalisib Phase II trial. On 16 January 2023 Kazia announced a placement to professional and sophisticated investors and the launch of an associated Share Purchase Plan for eligible shareholders. The placement of A$4,500,000, comprised of an unconditional placement of A$2,792,572 at $0.11 per share; and a conditional placement of A$1,707,428 at $0.11 per share, and was approved by shareholders at the Extraordinary General Meeting on 24 February 2023. Each placement was made to professional and sophisticated investors. The Placement was not underwritten. In addition, eligible shareholders were offered the opportunity to acquire up to A$30,000 of new shares through a Share Purchase Plan (SPP). All new shares issued under the Placement and the SPP ranked equally with the existing ordinary shares. Funding will be used to drive Kazia’s clinical program toward several critical inflection points through CY2023, including the final data read out on the paxalisib GBM AGILE study and for general working capital purposes. Funds raised by the SPP totalled A$2,606,000. No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the consolidated entity’s operations, the results of those operations, or the consolidated entity’s state of affairs in future financial years. |
Earnings per share |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings per share | Note 20. Earnings per share
8,640,000 unlisted options have been excluded from the above calculations as they were anti-dilutive. |
Reconciliation of loss after income tax to net cash used in operating activities |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of loss after income tax to net cash used in operating activities | Note 21. Reconciliation of loss after income tax to net cash used in operating activities
|
Significant accounting policies (Policies) |
6 Months Ended |
---|---|
Dec. 31, 2022 | |
Text block [abstract] | |
Basis of preparation | These general purpose financial statements for the interim half-year reporting period ended 31 December 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 ‘Interim Financial Reporting’ and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 ‘Interim Financial Reporting’. These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated. |
New or amended Accounting Standards and Interpretations adopted | New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. |
Going concern | Going concern During the half year ended 31 December 2022 the consolidated entity experienced net cash outflows from operating activities of $8,806,148 (December 2021: $11,391,410) and incurred a loss after tax of $13,586,027 (December 2021 restated: $13,201,848). As at 31 December 2022 the consolidated entity had cash in hand and at bank of $4,390,523. The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. An ‘at-the-market’ equity program (ATM) with Oppenheimer & Co. Inc. (Oppenheimer), as sales agent was established in May 2022. Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million of its ordinary shares, in the form of American Depository Shares (ADSs), with each ADS representing ten ordinary shares. Kazia entered into an Equity Distribution Agreement, dated 22 April 2022 (the Sales Agreement), with Oppenheimer, who acts as sales agent. As at 31 December 2022 net proceeds of A$9,560,357 have been raised. On 3 January 2023 a deposit of US$428,096 was received from Labcorp Early Development Laboratories Inc. representing the refund due on the completion of the Paxalisib Phase II trial. On 1 6 January 2023 Kazia announced a placement to professional and sophisticated investors and the launch of an associated Share Purchase Plan for eligible shareholders. The placement of A$4,500,000, comprised of an unconditional placement of A$2,792,572 at $0.11 per share; and a conditional placement of A$1,707,428 at $0.11 per share, and was approved by shareholders at the Extraordinary General Meeting on 24 February 2023. Each placement was made to professional and sophisticated investors. The Placement was not underwritten. In addition, eligible shareholders were offered the opportunity to acquire up to A$30,000 of new shares through a Share Purchase Plan (SPP). All new shares issued under the Placement and the SPP ranked equally with the existing ordinary shares. Funding will be used to drive Kazia’s clinical program toward several critical inflection points through CY2023, including the final data read out on the paxalisib GBM AGILE study and for general working capital purposes. Accordingly the directors have prepared the financial statements on a going concern basis. While the Company’s current cash balance is not sufficient to fund the operations for a period of 12 months from the date of this report, the directors have prepared the financial statements on a going concern basis as they are confident of the Company’s ability to raise additional funding, via licensing and partnering activities, obtaining of grant funding or raising additional capital from investors. Should the above assumptions not prove to be appropriate, there is material uncertainty related to events or conditions that may cast significant doubt whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. |
Restatement of comparatives (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Material Restatement Of EVT 801 Asset | The error resulted in a material overstatement of the EVT-801 asset and a corresponding overstatement of the liability at acquisition. The impact of this error is noted below with the restated balances disclosed in note 10,14 and 16:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Material Restatement Of Income Statement |
|
Other income (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of other income |
|
Expenses (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of expenses |
|
Cash and cash equivalents (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of cash and cash equivalents |
|
Trade and other receivables (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statement [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of current assets - trade and other receivables |
|
Other Assets (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of current assets - other |
|
Intangibles (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of non-current assets - intangibles |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of reconciliations of intangibles | Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
|
Trade and other receivables - non-current (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of non-current assets - trade and other receivables non-current |
|
Trade and other payables (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statement [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of trade and other payables |
|
Borrowings (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of detailed information about borrowings [text block] |
|
Contingent consideration (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statement [line items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of liabilities - contingent consideration |
|
Deferred tax (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of deferred taxes liability |
|
Contingent consideration - non-current (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of liabilities - contingent consideration |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of reconciliation of contingent consideration |
|
Contributed equity (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of equity - contributed equity |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of movements in ordinary share capital | Movements in spare share capital
|
Earnings per share (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of earnings per share |
|
Reconciliation of loss after income tax to net cash used in operating activities (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text block [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of reconciliation of profit or loss to operating cash flows |
|
Restatement of comparatives - Additional Information (Detail) |
Dec. 31, 2022 |
---|---|
Restatement of comparatives [Abstract] | |
Incremental borrowing rate | 6.00% |
Other income - Summary of other income (Detail) - AUD ($) |
6 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
Material income and expense [abstract] | ||
Government grant | $ 0 | $ 10,000 |
Bad debt recovery | 0 | 14,956 |
Other income | $ 0 | $ 24,956 |
Expenses - Summary of expenses (Detail) - AUD ($) |
6 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 |
Jun. 30, 2022 |
Dec. 31, 2021 |
|
Disclosure of expenses by nature [line items] | |||
Amortisation | $ 934,711 | $ 934,711 | |
Interest expense | |||
Contingent Consideration | 221,637 | $ 414,662 | 207,068 |
Superannuation expense | |||
Defined contribution superannuation expense | 63,734 | 93,960 | |
Employee benefits expense excluding superannuation | |||
Employee benefits expense excluding superannuation | 1,778,503 | 1,349,523 | |
Paxalisib licensing agreement [member] | |||
Disclosure of expenses by nature [line items] | |||
Amortisation | 542,177 | 542,177 | |
EVT801 Licensing Agreement [Member] | |||
Disclosure of expenses by nature [line items] | |||
Amortisation | $ 392,534 | $ 392,534 |
Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Cash and cash equivalents [abstract] | ||
Cash at bank and on hand | $ 4,390,523 | $ 7,361,112 |
Trade and other receivables - Summary of current assets - trade and other receivables (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Disclosure of financial assets [line items] | ||
Trade and other receivables | $ 741,128 | $ 90,975 |
GST Refundable [Member] | ||
Disclosure of financial assets [line items] | ||
Other current receivables | 69,093 | 51,353 |
PaxalisibPhase II Clinical Trial Refund [Member] | ||
Disclosure of financial assets [line items] | ||
Other current receivables | 631,876 | 0 |
Deposits Paid [Member] | ||
Disclosure of financial assets [line items] | ||
Other current receivables | 40,159 | 39,622 |
Refundable [Member] | ||
Disclosure of financial assets [line items] | ||
Other current receivables | $ 700,969 | $ 51,353 |
Trade and other receivables - Additional Information (Detail) |
Jan. 03, 2023
USD ($)
|
---|---|
Labcorp Early Development Laboratories Inc [Member] | Deposit Recieved [Member] | |
Disclosure of financial assets [line items] | |
Deposits | $ 428,096 |
Other assets - Summary of current assets - other (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Statement of financial position [abstract] | ||
Prepayments | $ 784,557 | $ 156,153 |
Intangibles - Summary of reconciliations of intangibles (Detail) - AUD ($) |
6 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
Disclosure of detailed information about intangible assets [line items] | ||
Beginning balance | $ 19,138,858 | |
Amortisation expense | (934,711) | $ (934,711) |
Ending balance | 18,204,147 | |
Paxalisib licensing agreement [member] | ||
Disclosure of detailed information about intangible assets [line items] | ||
Beginning balance | 10,241,410 | |
Amortisation expense | (542,177) | (542,177) |
Ending balance | 9,699,233 | |
EVT801 licensing agreement [Member] | ||
Disclosure of detailed information about intangible assets [line items] | ||
Beginning balance | 8,897,448 | |
Amortisation expense | (392,534) | $ (392,534) |
Ending balance | $ 8,504,914 |
Trade and other receivables - non-current - Summary of non-current assets - trade and other receivables noncurrent (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Disclosure of detailed information about trade and other receivables noncurrent [line items] | ||
Trade and other receivables - non-current | $ 3,715,248 | $ 7,300,870 |
GBM agile deposit [member] | ||
Disclosure of detailed information about trade and other receivables noncurrent [line items] | ||
Trade and other receivables - non-current | 3,672,325 | 7,257,947 |
Corporate credit card deposit [member] | ||
Disclosure of detailed information about trade and other receivables noncurrent [line items] | ||
Trade and other receivables - non-current | $ 42,923 | $ 42,923 |
Trade and other payables - Summary of current liabilities - trade and other payables (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Trade and other payables [abstract] | ||
Trade payables | $ 2,306,921 | $ 1,524,174 |
Accrued And Other Payables | 841,847 | 2,235,946 |
Total trade and other payables | $ 3,148,768 | $ 3,760,120 |
Borrowings - Schedule of borrowings (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Disclosure of detailed information about borrowings [line items] | ||
Current borrowings | $ 552,315 | $ 0 |
Insurance Premium Funding [Member] | ||
Disclosure of detailed information about borrowings [line items] | ||
Current borrowings | $ 552,315 | $ 0 |
Contingent consideration - Summary of liabilities - contingent consideration (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Disclosure of contingent liabilities [line items] | ||
Contingent Consideration Current | $ 1,438,461 | $ 758,840 |
Contingent consideration - Paxalisib [Member] | ||
Disclosure of contingent liabilities [line items] | ||
Contingent Consideration Current | 652,174 | 0 |
Contingent consideration – EVT801 [Member] | ||
Disclosure of contingent liabilities [line items] | ||
Contingent Consideration Current | $ 786,287 | $ 758,840 |
Deferred tax - Summary of deferred taxes liability (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Deferred tax assets and liabilities [abstract] | ||
Amount expected to be settled after more than 12 months | $ 2,424,815 | $ 2,560,361 |
Credited to profit or loss | $ (135,546) | $ (368,080) |
Contingent consideration - non-current - Summary of liabilities - contingent consideration (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Disclosure of contingent liabilities [line items] | ||
Contingent consideration non current | $ 8,118,317 | $ 8,208,945 |
Contingent consideration - Paxalisib [Member] | ||
Disclosure of contingent liabilities [line items] | ||
Contingent consideration non current | 600,588 | 1,167,536 |
Contingent consideration – EVT801 [Member] | ||
Disclosure of contingent liabilities [line items] | ||
Contingent consideration non current | $ 7,517,729 | $ 7,041,409 |
Contingent consideration - non-current - Summary of reconciliation of contingent consideration (Detail) - AUD ($) |
6 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 |
Jun. 30, 2022 |
Dec. 31, 2021 |
|
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items] | |||
Contingent Consideration | $ 8,967,785 | $ 11,094,441 | |
Interest | 221,637 | 414,662 | $ 207,068 |
Loss on revaluation of contingent consideration | 85,226 | 152,287 | 74,110 |
Contingent Consideration | 9,556,778 | 8,967,785 | $ 11,094,441 |
Contingent consideration [member] | |||
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items] | |||
Foreign currency loss | $ 282,130 | (328,873) | |
EVT801 Licensing Agreement [Member] | |||
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items] | |||
Payment of milestone | $ (2,364,732) |
Contingent consideration - non-current - Additional Information (Detail) |
6 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2022
AUD ($)
Milestone
|
Dec. 31, 2022
EUR (€)
Milestone
|
Dec. 31, 2021 |
Jun. 30, 2017 |
|
Disclosure of contingent liabilities [line items] | ||||
Milestone payments not booked | $ 472,558,578 | € 300,500,000 | ||
Milestone payment discount rate | 15.00% | 15.00% | 35.00% | |
Probability of milestone payments | 100.00% | 100.00% | ||
Percentage of discount rate on milestone payments | 6.00% | 6.00% | ||
Glioblast Pty Ltd [member] | ||||
Disclosure of contingent liabilities [line items] | ||||
Percentage of equity interests acquired | 100.00% | |||
Number of contingent milestone payments | Milestone | 4 | 4 | ||
Genentech agreement [member] | ||||
Disclosure of contingent liabilities [line items] | ||||
Contingent consideration | $ | $ 1,394,000 | |||
Number of contingent milestone payments | Milestone | 1 | 1 | ||
Milestone Two [member] | ||||
Disclosure of contingent liabilities [line items] | ||||
Contingent consideration | $ | $ 1,250,000 |
Contributed equity - Summary of equity - contributed equity (Detail) - AUD ($) |
Dec. 31, 2022 |
Jun. 30, 2022 |
---|---|---|
Disclosure of classes of share capital [abstract] | ||
Ordinary shares - fully paid, shares | 163,408,976 | 138,755,376 |
Ordinary shares - fully paid | $ 90,343,718 | $ 84,480,249 |
Earnings per share - Summary of earnings per share (Detail) - AUD ($) |
6 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
Earnings per share [abstract] | ||
Loss after income tax attributable to the owners of Kazia Therapeutics Limited | $ (13,586,027) | $ (13,201,848) |
Weighted average number of ordinary shares used in calculating basic earnings per share | 145,661,097 | 132,014,383 |
Weighted average number of ordinary shares used in calculating diluted earnings per share | 145,661,097 | 132,014,383 |
Basic earnings per share | $ (9.327) | $ (10) |
Diluted earnings per share | $ (9.327) | $ (10) |
Earnings per share - Additional Information (Detail) |
6 Months Ended |
---|---|
Dec. 31, 2022
shares
| |
Unlisted options [member] | |
Earnings per share [line items] | |
Number of options that have been excluded from the calculations as they were antidilutive | 8,640,000 |
-TS:?(@"BZ99GQ60^:S[[6,YG ,2,=K7T9O)D?5]+>!!<%Y53+\4&A;QV
MP.(>MU>,I]'%04$@A @E$2/O4ZHC<#J;@3SD?@[2PQDH'?PB6B2E]IU78C)*
MNB[0T?@(BIDMJ$N<$$XBC$><4_=%A<+>-1N,Q4&<1:C3C,B+XRB((_\8I'F,
M/, :HQ= ])L$4[.
M]4>7:X&A87B]A;>C[Z94#:YXL+WM")9M5=W#1J@26!*2B&8D3Q-@84;2."8A
MMG-*PB@D* &ULC5;;;N,V$'WW5PRTBX5=L-%=EK.V@5QZ6: I@F3;
M/A1]H*61Q48BM20=)W_?H60[#IH8^V+Q,C,\Y\P,Z?E6Z0=3(UIX:AMI%EYM
M;7?N^Z:HL>7F3'4H::=2NN66IGKMFTXC+WNGMO&C(,C\E@OI+>?]VJU>SM7&
M-D+BK0:S:5NNGR^Q4=N%%WK[A3NQKJU;\)?SCJ_Q'NT?W:VFF7^(4HH6I1%*
M@L9JX5V$YY>)L^\-_A2X-4=C<$Q62CVXR9=RX04.$#986!>!T^<1K[!I7"""
M\6T7TSL C YF]RMFCI;:#I/
MO:V#1D=T5.Y6S5F+IOT+D,(@B/T#>Z)W7M!LO6SLB<;89Y0?V2;&2DZFQ!*:
M?C;3&T+?.]OIC%4W: M-YZEW@[[111W;)FVV2=AM&\<#]0H'QVQF'_:R'?"?
M?+UYY9,G^7^UJ1[WSY7VA>'&?G5OZU)[Q% $"B;DT'(8,
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M_Z?_(9OW*(040TN[PU"?J!DQGX'XDQLJ_NA1H)>:'">!"XV@C7
07X[X=(,K\.Z7-?CNK]]?+X6,UODLLP'Y_1$9SR#_JQ:L,+BM[&ZK
MNA)-?G<0?/,RB%]+7M[QYK\&L+4=[&>QXPVX##*V0W[B+6\>9)(L$(D=0O:0
M[)!*TMLTO,J>@6A8U19,'-N[QP>__C0+G]KAWV79H3Q(.'F[/]9M.SO6I:R5
M4\'@4\'@'IW.H+_G]WE5Y=4]>,\*5F4/>QX0]Y?6B+9]"*/NQ+O.\!$^"?
MA^H-(/ '@"%&ICHZ!O3Z@-W4^7!+@M"# 8JNEP^O*TWK:)36HU"3Y B7HTD/34DJSC
MIVV(.=MZES,D/JP3-#%!GNQ)^?$A]FYB6I%86X8W>/,&MYY[%1)];\0USL*&
M2AS-OGP^CLGR:X-@E0IW'R=>RZIY#YE]D"'FX*/.N^.,H/32D'U+[KQ84R%C
MNL"-@$>#SW+-)=L77Q'_V!R@*1-_D__6$KQ-.;=0+N4^^MP#'G%E9JZV <%BP-TU'R9/U2!PM3TI%EA=
_OA#,H_?G0ER>@AR>L[Z_U&=LW9/1_U7[01+
MYB/VV[P.(&:UD@5WHAB@/*)<"L/^W%3"UVA '^R+L(X$V!\&K]BKP1G3#_R)
M*VGEDLWC.)IE&4NB9+Z(9I/Y.;6/OWS+XH1!+EE$B_0*W^)I$DWCJT$6)4D6
M39(%RZ(TSJ*KZ6QPQVIMO*I>,;<1K) VUPT,\[I6$H$ZS3B\Y;+V<:\:UQC!
M:KX'%3G+-MRRIMI!I8C0JV[CK2")H 'H,5GE($
S,AFMR%DL
M=A5,'"F+=,^?8=]'X"L@W@? , $5RK\'B,,(E"M=@&'<2??4$%5?8-%NW?VA
MY!(4-&P#GZ;A@"YV$VM2TW!E;M -F@>*-[@=<_@[NO;^_=VC"GY\?H4=AK#5
M8KFU[M//K-KQI%$M* ^.S:=ESZEP&B6^KE$X#4,W+UX-0/]/I^P8 6<'[YV.
M]-J_Z@P&TU;:_NFSE^X?CE?]>^F;>O_J?,?U6DC#6EK!-)P68)GN7W+]QJJ-
M?STME<5;S"\;/'Y).P6
<1'0.QT^T1.Y2/1
M))U)T2)IHPV;-5RI#FW$46XO9:VE^4L-3J=+HDI$>(%R:\!K0_>$ =<*O7LA
M&0/U?A9HD\=&!_F1<^$YXRN<8_0DN"X5^L0+*/['!T9?)S(^B5S$-PD?(1^@
M).JC.(SC&WQ)5W3B^)(K?"]PT"AC(M^A7R136IK>^'VI3D\SO$QCYV6J:I+#
M')N!4"#W@-.W;Z)Q^/&&R&$GK!:H_/'"EUI@8SV@-LX!
MWO)"TR*+9UM;
M9.:(4FC86N*.2G'[M )INIQ.Z?E@)PX-A@-69"T_P#W@]W9KO<5&EDHHT$X8
M32S4.5U.%ZM9\(\./P1T[F)/0B9[8QZ"L:ERF@1!(*'$P,#]
VK:(%I 0<<&6D*H[,\83(M62SVVQY$"F65(2VZ[C
M!'9":&KUN]FU$>]WV4K&-(411V*5)(3_O8:8;7H6MK87[NA\(?4%N]]=DCF,
M03XL1URM[!)E2A-(!64IXC#K65?X